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Rui Du1? , Shanshan Wu1? , Xiaoning Lv2? , Henghu Fang1, Sudong Wu1 and Jingbo Kang1*Abstract
Aims: Brachyury overexpression has been reported in various human malignant neoplasms, but its expression and
function in hepatocellular carcinoma progression and metastasis remains unknown. The present study aimed to
evaluate the critical role of Brachyury in HCC metastasis.
Methods: The expression of Brachyury in human HCC (SMMC7721, HepG2, FHCC98, and Hep3B) and control cell
lines was analyzed using quantitative reverse-transcriptase polymerase chain reaction and immunoflourence methods.
Cancerous tissues collected from patients with HCC (n = 112) were analyzed using immunohistochemical method; a
microarray analysis of HCC tissues was performed to explore the clinicopathological variables of HCC. The migratory
and invasive capacities of Brachyury-SMMC7721 and Brachyury-HepG2 transfected cells were evaluated using in vitro
scratch wound healing and Matrigel invasion assays, respectively. Further, six-week-old male BALB/c nude mice (n = 10)
model was used in vivo assay.
Results: Elevated expression of Brachyury was detected in HCCs (62.5%) compared with that in adjacent nontumorous
tissues. Clinicopathological analysis revealed a close correlation of Brachyury expression with distant metastasis and
poor prognosis of HCC. Overexpression of Brachyury promoted epithelial-mesenchymal transition (EMT) and metastasis
of HCC cells in vitro and in vivo. Brachyury overexpression enhanced Akt activation by inhibiting phosphatase and
tensin homolog (PTEN), which led to subsequent stabilization of Snail, a critical EMT mediator.
Conclusion: The study findings suggest that elevated Brachyury facilitates HCC metastasis by promoting EMT via
PTEN/Akt/Snail-dependent pathway. Brachyury plays a pivotal role in HCC metastasis and may serve as a novel
prognostic biomarker and therapeutic target.
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PTEN/Akt/Snail-Dependent PathwayIntroduction
Hepatocellular carcinoma (HCC) is ranked as the fifth
most frequent cancer and third most frequent cause of
cancer deaths in the world [1]. In spite of improvements
in surveillance and clinical therapeutic strategy, long-term
disease-free survival (DFS) of patients with HCC remains
unsatisfactory due to tumor recurrence and metastasis
of the primary tumor [2,3]. Metastasis is not only a
complex process but also the major cause of cancer-* Correspondence: Kjbnet@126.com
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unless otherwise stated.related deaths [4]. Epithelial-mesenchymal transition
(EMT) describes a series of events during which cells lose
epithelial characteristics such as cell-layer organization
and apical-basolateral polarization and acquire properties
of mesenchymal or fibroblastoid cells including motility
[5]. EMT is known to be a central mechanism responsible
for invasiveness and metastasis of various cancers [6,7].
Increasing evidences suggest that activation of Rho-family
of small GTPases, cytoskeletal rearrangement, and nuclear
translocation of several transcription factors such as Snail
and Twist play important roles in the processes of cancer
cell metastasis through modulation of cancer cells EMTis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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related EMTare not fully elucidated.
The T-box transcription factor, Brachyury, is vital for
the formation and differentiation of posterior mesoderm
and axial development in vertebrates [11]. Interestingly,
Brachyury is located at 6q27, which is a frequently amp-
lified region in HCC [12]. The function of Brachyury has
extensively been characterized in mice and zebrafish
[13,14]. An earlier study on Brachyury-mutant mice
model without T protein reported in utero death with
abnormal notochord, absent somites, and reduced allan-
tois [15]. In zebrafish, the no-tail mutation (Ntl) is the
homolog of Brachyury; the Ntl embryos die soon after
hatching with lack notochords and tails, and they pos-
sess abnormal trunk somites. The T gene encodes a tran-
scription factor that binds to a specific DNA element via
its N-terminal region [14]. In humans, T-box transcrip-
tion factors are major players in the regulation of the
progenitors and their differentiated descendants [11,16].
Brachyury is expressed in the progenitor population
throughout somitogenesis, suggesting that it plays an es-
sential role in keeping the progenitor population viable
[17]. Meanwhile, Brachyury is also dysregulated in various
human malignant neoplasms [18,19]. Recently, Brachyury
was demonstrated to induce EMT in human epithelial
cells through induction Snail, Slug, and downstream signal
[20]. An earlier study on human lung carcinoma cells
(in vitro and in vivo) has demonstrated that overexpressed
Brachyury divides at slower rates than those with low-
expressed Brachyury, a phenomenon associated with
marked downregulation of cyclin D1, phosphorylated Rb,
and CDKN1A (p21) [21]. Another study on oral squa-
mous cell carcinoma cells demonstrated that the expres-
sion of Brachyury was correlated with EMT and was
significantly associated with lymph node and distant me-
tastasis [22]. The above evidences indicate that Brachyury
may be a critical regulator of carcinogenesis and tumor
metastases in different cancers. Until now, no studies have
reported its roles in HCC. Hence, the present study aimed
to evaluate the Brachyury expression in patients with
HCC and in HCC cell lines and its clinicopathological sig-
nificance in HCC.Materials and methods
Cell culture
Human simian virus 40-transformed immortal liver epi-
thelial cells (QZG) and HCC cell lines SMMC7721,
HepG2, FHCC98, and Hep3B were purchased (Bei Na
Biotechnology Research Institute, Beijing, China) and
preserved [23]. Cells were maintained at 37?C with 5%
carbon dioxide in Dulbecco ? s Modified Eagle ? s Medium
(DMEM) (Gibco? Life Technologies, Grand Island, USA),
supplemented with 50 units/ml penicillin, 50 mg/mlstreptomycin, and 10% fetal calf serum (Gibco? Life
Technologies, Burlington, Canada).
Patients and tissue samples
Patients (n = 40; aged between 32 and 79 years with a
mean age of 50.12 ? 15.02 years), who underwent hepatec-
tomy for HCC between January 2006 and August 2008 in
the Department of General Surgery, Xijing Hospital (Xi? an,
China), were included in the Brachyury and vimentin cor-
relation analysis. Tissue chips for HCC primary tumors
were purchased from National Engineering Center for
Biochip Design, Shanghai Biochip Co. Ltd., Shanghai,
China. The tissue chips (n = 72) were used in the clinico-
pathological correlation and survival analysis. None of
these patients received preoperative chemotherapy or
radiotherapy. All tumor samples were derived from dis-
sected tumor tissues and were composed of more than
90% of tumor cells without necrosis. The surgical speci-
mens (both tumor and adjacent nontumorous tissues)
were processed immediately after the operation and snap-
frozen in liquid nitrogen for protein, DNA, and ribo-
nucleic acid (RNA) extraction. All patients with HCC gave
written informed consent on the use of clinical specimens
for medical research. Studies using human tissues were
reviewed and approved by the Committees for Ethical
Review of research involving human subjects of Fourth
Military Medical University, Xi ? an, China.
Immunohistochemistry (IHC) and Immunofluorescence (IF)
For IF analysis, SMMC7721 and HepG2 cells were cul-
tured on sterile glass coverslips in 24-well plates. The
slides were fixed with 95% alcohol for 15 minutes at room
temperature. The coverslips were washed with phosphate-
buffered saline (PBS) and permeabilized for 5 minutes
with 0.5% Triton X-100 in PBS. The cells were then incu-
bated with primary antibodies including anti-E-cadherin
and anti-vimentin (1:100 ratios; Santa Cruz Biotechnology,
Santa Cruz, USA) after blocking with 10% normal goat or
rabbit serum for 1 h. The slides were incubated with fluor-
escein isothiocyanate-conjugated goat anti-mouse or anti-
rabbit Immunoglobulin G (IgG) as the secondary antibody
at room temperature for 1 h. Slides were examined with a
Nikon (Melville, USA) Eclipse TE300 fluorescence
microscope, and the pictures were taken with a SPOT
Diagnostic CCD camera (SPOT ? Imaging Solutions,
Sterling Heights, USA).
The paraffin-embedded tissue blocks were sectioned for
IHC analysis. In brief, tissue sections were deparaffinized
and rehydrated. The endogenous peroxidase activity was
blocked with 3% hydrogen peroxide for 10 minutes. For
antigen retrieval, slides were immersed in 10 mM citrate
buffer (pH 6.0) and boiled for 15 minutes in a microwave
oven. Nonspecific binding was blocked by 5% normal goat
serum for 10 minutes. The slides were incubated with
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Abcam, USA), anti-E-cadherin antibody, and anti-Snail
polyclonal antibody (diluted at 1:200 ratio; Santa Cruz
Biotechnology, Santa Cruz, USA) at 4?C overnight in a
moist chamber. The slides were sequentially incubated
with biotinylated goat anti-mouse IgG (1:100 dilution;
Santa Cruz Biotechnology, Santa Cruz, USA) and then
with streptavidin-peroxidase conjugate, each for 30 mi-
nutes at room temperature. Isotope-matched human
IgG was used in each case as a negative control. Finally,
the 3, 5-diaminobenzidine Substrate Kit (Dako, Glostrup,
Denmark) was used for color development followed by
Mayer ? s hematoxylin counter staining. The slides were
counterstained with hematoxylin, dehydrated and mounted.
Tumor cell proportions were scored as follows: 0 (no
positive tumor cells); 1 (<25% positive tumor cells); 2
(25? 50% positive tumor cells); and 3 (>50% positive tumor
cells). Staining intensity was graded according to the fol-
lowing standard: 0 (no staining); 1 (weak staining = light
yellow); 2 (moderate staining = yellow brown) and 3
(strong staining = brown). The staining index (SI) was
calculated as the product of the staining intensity score
and the proportion of positive tumor cells. Using this
method, we evaluated nuclear Brachyury expression in
HCC tumor tissues and adjacent nontumorous ones by
determining the SI, with scores of 0, 1, 2, 3, 4, 6, 8, 9. Only
2+ and 3+ was considered as a positive IHC result [20].
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was isolated using Trizol reagent (Life
Technologies, China), reverse transcribed with TaKaRa
reverse transcription Kit (TaKaRa, Dalian, China) start-
ing with 2 μg total RNA from each sample per manu-
facturer ? s instructions. The messenger ribonucleic acid
(mRNA) expressions of Brachyury and housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were analyzed by quantitative RT-PCR using a real-time
LightCycler? rapid thermal cycler (Roche Molecular
Biochemicals LightCycler System, Shanghai, China). Spe-
cific Brachyury primers 5? -ACTGAGAATCAGCCGGA
CTT-3? (forward) 5? -CTGCACTGCAAAGAACCACT-3?
(reverse) and internal control GAPDH primers 5? -GCA
CCGTCAAGGCTGAGAAC-3? (forward) and 5? -TGGTG
AAGACGCCAGTGGAT-3 ? (reverse) were used for
mRNA amplifications. For quantitative RT-PCR, 1 μl
of gene primers with SYBR? Green (Applied Biosystems,
China) in 25 μl of reaction volume was used. The MTBP
mRNA levels were normalized to GAPDH mRNA accord-
ing to the following formula: 2-(CT target ? CT GAPDH), where
CT was the threshold cycle.
Plasmids and cell transfection
Human Brachyury was amplified by the PCR using
cDNA from SMMC7721, confirmed by sequencing andsubcloned into pCDNA3.1 expression vector(Invitrogen,
Carlsbad, USA). Cell transfection was carried out by plat-
ing 2 ? 10 5 HepG2 and SMMC7721 cells on six-well plate
and transfected with 800-ng constructs using Lipofecta-
mine? 2000 (Invitrogen Life Technology, Carlsbad, USA)
per manufacturer ? s instructions. Briefly, cells grew 70% to
90% confluence before transfection. The pcDNA3.1-
Brachyury and pcDNA3.1-control were transfected using
Lipofectamine? 2000 in DMEM. The cells were selected
for more than 4 weeks by incubation with G418 (Invitro-
gen, 400 ng/ml for SMMC-7721 and 600 ng/ml for
HepG2) for overexpression clones. Stable single clones
were selected and Brachyury expression assessed using
western blotting. Transient transfection of pcDNA3.1-
Brachyury and the control constructs into HCC cells
were performed using Lipofectamine 2000.
Protein preparation and Western blot analysis
Harvested cells (2 ? 10 6) were placed in 1.5-ml Eppendorf
tubes and homogenized with 400 μl lysis buffer (50 mM
Tris-hydrochloride, pH 8.0, 150 mM sodium chloride,
0.1% sodium dodecyl sulfate, 1% Nonidet P-40, 0.5% so-
dium deoxycholate, 0.02% sodium azide, 100 μg/ml phe-
nylmethanesulfonyl fluoride, and 1 μg/ml aprotinin). Cell
lysates were centrifuged at 4?C for 5 minutes at
10,000 rpm, and the protein-containing supernatant was
placed in fresh tubes and quantified using the Bradford
protein assay.
Western blot analysis was performed as described previ-
ously [24]. In brief, the membranes with total protein were
incubated with primary antibodies: anti-Brachyury and
anti-Snail (1:1000 dilutions; Cell Signaling Technology,
Danvers, USA), anti-E-cadherin, anti-γ-catenin, anti-
vimentin, anti-Akt, anti-p-Akt, and anti-PTEN (1:200
dilution; Santa Cruz Biotechnology, Santa Cruz, USA).
After repeated washing, the membranes were incubated
with horseradish-peroxidase-conjugated anti-rabbit or
anti-mouse secondary antibody (1:2000 dilution; Santa
Cruz Biotechnology, Santa Cruz, USA). The bands were
visualized using the enhanced chemiluminescence detec-
tion system (Amersham Pharmacia Biotech, Piscataway,
NJ, USA) and exposed to Kodak X-OMAT film (Rochester,
USA). β-actin was used as an internal sample loading
control. Autoradiograms were quantified using densi-
tometry (Bio Image Intelligent Quantifier software, Bio
Image Systems Inc., Jackson, MI, USA). Relative protein
levels were calculated by normalization to the amount
of β-actin protein.
Wound healing and invasion assays
Wound-healing assay and invasion assay were performed
as described previously [12]. Cell migration was assessed
by measuring the movement of cells into a scraped; a
cellular area was created using a 200-μl pipette tube, and
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and photographed under a microscope. The % wound
healing was quantified by the space of migration tumor
cells at 24 h after scrambled /the space of wound at
0 h ? 100%. Cell invasion was quantified in vitro using
Transwell chambers with polycarbonate membrane fil-
ters (8-μm pore size) coated with a Matrigel ? (Sigma, St.
Louis, USA). Briefly, 48 hours after transfection, cells
were washed twice using DMEM and seeded in triplicate
in the inner chamber of the insert containing 200 μl of
serum-free medium. About 700 μl of medium containing
10% fetal bovine serum was added to the lower chamber.
The plates were incubated for 24 hours at 37?C. Then,
the noninvading cells from the interior of the inserts
were gently removed using a cotton-tipped swab. The
cells that had invaded into the bottom surface of the filter
were fixed with methanol and stained with hematoxylin.
The invasive ability was determined by counting the pene-
trating cells under a microscope at ? 200 magnification on
10 random fields in each well. The experiments were per-
formed in triplicate.In vivo metastasis assay
Six-week-old male BALB/c nude mice (n = 10) were ran-
domized into two groups. HepG2/Brachyury or control
cells (2 ? 10 6) were injected into the tail vein of nude
mice. Four mice were sacrificed 6 weeks post inoculation
and consecutive sections of the whole lung were subjected
to hematoxylin and eosin staining. All of the metastatic
foci in lung were calculated microscopically to evaluate
the development of pulmonary metastasis. The remaining
mice were monitored for survival analysis.Statistical analysis
Unless otherwise indicated, data were presented as mean
? standard deviation of three independent experiments.
SPSS statistical package for Windows (Version 12.0, SPSS
Inc. Chicago, IL, USA) was used for data analysis. Based
on staining intensities, the Brachyury immunoreactivity
was scored as negative (0 to 1) and positive (2 to 3) ac-
cording to a previously reported semiquantitative scor-
ing method [25]. The clinicopathological features of
Brachyury-positive and Brachyury-negative patients were
compared using Pearson χ2 test for categorical variables
and independent Student? s t-test for continuous data.
Comparisons of three or more variables were performed
using one-way analysis of variance followed by Fisher ? s
protected least significant difference test. Kaplan-Meier
plots and log-rank tests were used for survival analysis.
The DFS times were calculated from data of curative
surgery to HCC recurrence, death, or the last follow-up
data. For tissue microarray analysis, based on IHC scores,
Brachyury protein levels in primary HCC tissues andtheir matched metastatic tissues were compared using
Wilcoxon signed-rank test. The correlation between
mRNA levels of Brachyury and Snail was analyzed using
Pearson χ2 test. A P value less than 0.05 was considered
statistically significant.Results
Expression of brachyury is upregulated in human HCCs
To explore the role of Brachyury in HCC development, the
expression of Brachyury in various human HCC cell lines
were evaluated. As shown in Figure 1A, elevated expres-
sion of Brachyury was observed in all four HCC cell lines
compared with that in QZG cell lines. Brachyury mRNA
was significantly increased in HCCs relative to paired non-
cancerous tissues of 40 patients (Figure 1B), which was fur-
ther confirmed by Western blot assay (Figure 1C,D).
Immunohistochemical analysis showed little positive stain-
ing of Brachyury in nontumorous liver cells, but strong
nuclei staining of Brachyury (upregulated) in 62.5%
(70/112) of the patients with HCC. Brachyury was pre-
dominantly located in the nuclei of hepatocytes and
tumor cells (Figure 1E). Brachyury positive expression
was found in tumor tissues at a value (62.5%, 70 of 112
patients) higher than that in adjacent cirrhosis tissues
(23.2%, 26 of 112 patients) (P < 0.05).Brachyury overexpression predicts poor prognosis of HCC
To investigate the clinical significance of Brachyury
overexpression in HCC, microarray analysis of HCC tis-
sues from 72 patients who underwent liver resection and
40 PPEP tissues was performed (Table 1). The Mann-
Whitney U test was used to assess the correlations be-
tween the staining intensity of Brachyury protein and
clinicopathologic variables of HCC. As shown in Table 2,
the Brachyury expression in patients with HCC was corre-
lated with tumor size (P = 0.037), intrahepatic invasion
(P = 0.025), distance metastasis (P = 0.039). However, the
Brachyury protein staining intensity showed no significant
relationship with gender, age, α-fetoprotein and HBV in-
fection. Based on the results from IHC, all 112 patients
with HCC were divided into two groups: Brachyury-
positive expression group (n = 70) and Brachyury-negative
expression group (n = 42). Patients in positive expression
group exhibited shorter 5-year overall survival (OS, me-
dian OS were 16 and 43 months, respectively, difference
of 27 months, P = 0.004) than those in negative expression
group (Figure 2A). Consistently, the 3-year OS rate after
surgery was much lower in Brachyury-positive group than
that in Brachyury-negative group (Figure 2B). Thus,
Brachyury overexpression could serve as a valuable pre-
dicting factor for recurrence and poor survival of patients
with HCC.
Figure 1 Expression of Brachyury is up-regulated in human HCCs. (A) Expression of Brachyury in one human normal liver cell lines (QZG)
and four hepatoma cell lines was examined by western blot assay. (B) Brachyury expression in 40 pairs of HCC and the surrounding tissues were
detected by real-time PCR. (C) Representative western blot showing the expression of Brachyury protein in tumor tissue (T) and paired peri-tumor
tissue (N) from eight HCC patients. (D) Relative immunohistochemical staining of Brachyury expression in paired HCC tissue samples (n = 112),
and the representative view (E).
Du et al. Journal of Experimental & Clinical Cancer Research 2014, 33:105 Page 5 of 11
http://www.jeccr.com/content/33/1/105Brachyury enhances invasive and metastatic potential of
HCC
The EMT promotes tumor progression by increasing the
invasiveness and migratory capacity of the tumor cells.
To test whether Brachyury-SMMC7721 and Brachyury-
HepG2 cells acquired greater migratory and invasive
capabilities, in vitro scratch wound healing and Matrigel
invasion assays were performed. The Matrigel invasion
assay showed that the invasiveness of the Brachyury-
expressing cells was significantly higher than emptyvector-transfected cells (P < 0.001, independent Student? s t
test; Figure 3A). Similarly, the wound healing assay dem-
onstrated that the ectopic expression of Brachyury in-
creased the cell motility in both Brachyury-SMMC7721
and Brachyury-HepG2 cells compared with Vec-
SMMC7721 and Vec-HepG2 cells (Figure 3B). To fur-
ther verify the effect of Brachyury on tumor metastasis,
in vivo metastasis assay was performed in nude mice.
Brachyury-HepG2 cells were injected into nude mice via
tail vein, Empty vector trasfected cells were used as
Table 1 Summary of clinicopathologic variables






























Table 2 Relationship between Brachyury expression and





Sex Male 60 32 0.797
Female 12 8
Age <55 45 27 0.683
≥55 27 13
AFP <100 32 15 0.551
≥100 40 25
HBV Positive 58 32 0.807
Negative 13 8
Liver Cirrhosis Yes 47 19 0.075
No 25 21
Tumor size (cm) <3 19 18 0.037
≥3 53 22
Intrahepatic Metastasis Y 32 9 0.025
N 40 31
Distant Metastasis Y 22 5 0.039
N 50 35
TNM Stage I 15 12 0.401
II 40 22
III 17 6
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lesions were microscopically detected in the lungs of nude
mice inoculated with Brachyury-HepG2 compared to that
in the control group (P < 0.001, independent Student? s t
test; Figure 3C). These data suggested that Brachyury pro-
moted HCC invasion and metastasis.
Brachyury promotes EMT in HCC cells
As EMT has been accepted as a potential mechanism
underlying cancer metastasis, we explored the role of
Brachyury in regulating EMT in HCC cells, Up-regulation
of Brachyury in HepG2 cells resulted in the decreased ex-
pression of epithelial markers (E-cadherin and γ-catenin)
and increased expression of mesenchymal marker (snail),
as evidenced by immunofluorescence staining (Figure 4A).
Western blot analysis also revealed that the protein levelof vimentin (mesenchymal marker) was increased, while
E-cadherin and γ-catenin were decreased in Brachyury-
overexpressing cells compared with control cells
(Figure 4B).
A similar result was observed in tissue samples of HCC.
The expression of E-cadherin and vimentin in 40 HCC
samples were analyzed using Western blotting. As shown
in Figure 4C, high expression of vimentin (T/NT ≥ 2) ac-
companied by low expression of E-cadherin (T/NT < 0.5)
was detected in HCC specimens with Brachyury overex-
pression (T/NT ≥ 2). High expression of vimentin and low
expression of E-cadherin was detected at 79.2% (19/24)
and 66.7% (16/24) in high-Brachyury expression HCC
specimens (T/NT ≥ 2), respectively. Conversely, high
expression of vimentin and low expression of E-cadherin
was only detected at 31.3% (5/16) and 25.0% (4/16) in
low-Brachyury expression HCCs (Table 3). Moreover, by
linear analysis, it was found that Brachyury expression
was positively correlated with vimentin (p < 0.001) and in-
versely correlated with E-cadherin (p < 0.01) (Figure 4D,E).
These data further support the involvement of Brachyury
in EMTas observed in HCC cells.
Brachyury regulates EMT via PTEN/AKT/Snail pathway
Numerous studies have suggested that Akt activation
plays a pivotal role in tumor progression via induction of
Figure 2 Brachyury overexpression predicts poor prognosis of HCC. (A) HCC patients were divided into Brachyury-positive expression group
(n = 70) and Brachyury-negative expression group (n = 40). The 5-year overall of 112 HCC patients were compared between the low and high
Brachyury groups. (B) The 3-year overall of 112 HCC patients were compared between the low and high Brachyury groups.
Figure 3 Brachyury enhances metastatic potential of HCC cells. (A) The invasive properties of the cells were analyzed in by an invasion assay
using a Matrigelcoated Boyden chamber. Migrated cells were plotted as the average number of cells per field of view from 3 different experiments, as
described in Materials and Methods. (B) The cell migration rate between SMMC-7721/Brachyury and SMMC-7721/GFP cells was compared by wound-
healing assay. Microscopic observation was recorded at 0 and 24 hours after scratching the cell layer. (C) Representative view of lung tissue sections
from each group are shown (H&E stain; magnification ? 100). The number of lung metastatic foci in each group (n = 10) of HepG2/Brachyury or
HepG2/GFP xenografted mice was calculated microscopically 6 weeks after tail vein injection. *p < 0.05.
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Figure 4 Brachyury promotes EMT in HCC cells. (A) HepG2/ Brachyury and control cells were cultured on Poly-L-Lysine coated glass coverslips
for 24 hours followed by immunofluorescence assay. (B) Relative expression of E-cadherin, γ-catenin, and Vimentin in HepG2/ Brachyury cells
compared to control cells. (C) Representative view of Western blot assay of E-cadherin and Vimentin in tumor tissue (T) and paired peri-tumor
tissue (N) from HCC patients with up-regulated Brachyury in tumor. (D) Scatter plot with fitted values intervals for T/NT (ratio of tumor tissue and
paired peri-tumor tissue) expression of Bachyury and Vimentin. (E) Scatter plot with fitted values intervals for T/NT expression of Bachyury
and E-cadherin.
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downregulated by tumor suppressor PTEN. Western blot
revealed that PTEN expression was significantly influ-
enced by Brachyury overexpression (Figure 5A), and itconfirmed the involvement of PTEN in Brachyury-
mediated Akt activation. Snail has been documented to
be regulated by Akt and is a predominant mediator of
EMT [30,31]. To test if Snail was involved in Brachyury-
Table 3 Relationship between Brachyury expression and
vimentin/E-cadherin in 40 HCC tissues
Vimentin T/NT E-cadherin T/NT
≥2 <2 >0.5 ≤0.5
Brachyury T/NT ≥2 19 5 8 16
<2 5 11 12 4
p-Value 0.001 0.01
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tion was examined. As expected, expression of Snail
was significantly increased in cells with Brachyury-
overexpression.
The Akt/Snail pathway involvement in EMT-mediated
Brachyury-overexpressed HCC cells was investigated.
Brachyury-HepG2 cells were treated with Akt inhibitor
(LY290004) and small interfering RNA (siRNA) against
Snail, and the effects on cell EMT were determined as
described previously. As shown in Figure 5, treatment
with Akt inhibitor prevented the Brachyury-mediated
increase in p-Akt and Snail (Figure 5B). Transfection
with siRNA against Snail effectively abolished Brachyury-
induced Snail expression (Figure 5C). The expression of
E-cadherin was correspondingly increased while vimentinFigure 5 Bachyury regulates EMT via Akt/Snail pathway. (A) Western b
enhanced p-Akt, Snail, but not t-Akt expression in HepG2 cells. (B) AKT inh
expression and abolished Bachyury-induced HCC EMT phenotype. (C) SiRN
EMT phenotype.was reduced in Brachyury-transfected cells after treatment
with Akt inhibitor or Snail siRNA. These results indicate
that Brachyury mediates the mesenchymal transition of
HCC cells through the Akt/Snail pathway.
Discussion
Recently, accumulating evidence has suggested that T-
Brachyury plays an important role in carcinogenesis and
metastasis of multiple types of human cancers, and may
serve as a prognosis marker. Nerbil et al. found that
early stages colorectal cancer patients (T1-2N0M0,
Dukes A) showed a significantly decreased survival when
Brachyury was expressed in the tumour tissue while no
correlation was observed in later tumour stages, suggest-
ing a possibility to detect metastatic cancers during early
stages of colorectal carcinogenesis by using an antibody
against brachyury in immunohistochemistry analysis
[18]. Brachyury was shown to be overexpressed in hu-
man lung tumors [32]. Furthermore, Brachyury mRNA
expression in primary lung carcinoma tissues was dem-
onstrated as a significant predictor of poor prognosis for
5-year disease-free survival and overall survival rates and
was significantly correlated to vascular invasion, lymph-
atic permeation, histological grade, pathologic T stage,lot assay demonstrated overexpression Bachyury repressed PTEN and
ibitor prevented the Brachyury-mediated increase in p-AKT and Snail
A against snail abolished Bachyury-induced Snail expression and HCC
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leagues also revealed that overexpression of brachyury in
breast carcinomas is associated with poor prognosis
[34]. More recently, Brachyury was shown to be overex-
pressed in prostate cancer and metastatic tumors when
compared with normal tissues and play an important
role in prostate cancer aggressiveness [35]. Here, we pre-
sented for the first time that the Brachyury was highly
expressed in HCC tissues compared with adjacent non-
tumorous tissues; Brachyury expression was correlated
with tumor size (P = 0.037), intrahepatic invasion (P =
0.025), distance metastasis (P = 0.039), and outcome of
HCCs, adding to the evidence that Brachyury may serve
as a prognosis marker and potential therapeutic target
for HCC.
The EMT usually occurs in the critical phases of em-
bryonic development and organ fibrosis. This program
has also been shown to be the pivotal mechanism con-
tributing to cancer metastasis [36]. It is well established
that EMT gives rise to the dissemination of single car-
cinoma cell from the site of the primary tumor [37]. The
EMT has also been reported to be involved in the pro-
gression of HCC and correlates with the prognosis of
cancer metastasis [12]. Recently, Brachyury has been
identified as an important EMT regulator by modulating
Slug and E-cadherin expression in various tumor cells;
however, whether Brachyury promotes hepatoma cells
EMT and cancer metastasis is not clear so far. The study
data suggest that Brachyury promotes hepatoma cells
metastasis through modulation of its EMT phenotype.
This notion was based on the findings as follows: (1)
Mesenchymal markers were significantly upregulated in
the Brachyury overexpression HCC cell lines, whereas
the epithelial markers were remarkably decreased by im-
munocytochemical analysis. (2) These results were fur-
ther confirmed by immunostaining analysis of cultured
cells and HCC tissues. (3) In vitro and in vivo metastasis
assays demonstrated that enforced Brachyury enhanced
the metastasis potential of HCC cells and induced more
metastatic lesions in liver of nude mice. Therefore, these
experimental data indicated that Brachyury might pro-
mote HCC metastasis through, at least partially, induc-
tion of EMT in hepatoma cells.
Brachyury was recently demonstrated to induce EMT
in human epithelial cells through repression of E-
cadherin and induction Slug [20]. Another study demon-
strates that Brachyury expression is enhanced during
TGF-β1-induced EMT in various human cancer cell
lines, and a positive feedback loop is established between
Brachyury and TGF-β1 in mesenchymal-like tumor cells.
Interestingly, Brachyury overexpression could promote
TGF-β1 upregulation by activating its promoter, while
inhibition of its signaling could decrease Brachyury ex-
pression, induce a mesenchymal-to-epithelial transition,and provide increased susceptibility to tumor cells to-
wards chemotherapy [38]. The present study focused on
the regulation of AKT pathway, because increasing evi-
dence had demonstrated that activated AKT pathway
could play a central role in EMT process and tumor me-
tastasis [26-29]. Activation of Akt in Brachyury-induced
EMT was observed in the study, correlating with vimen-
tin induction and E-cadherin downregulation. Further,
Snail has been documented to be regulated by Akt, and
it has been a predominant mediator of EMT [30,31].
The experimental data of present study showed that ex-
pression of Snail was significantly increased in cells with
Brachyury overexpression. Additionally, treatment with
Akt inhibitor prevented the Brachyury-mediated increase
in p-Akt and Snail, and transfection with siRNA against
Snail effectively abolished Brachyury-induced Snail ex-
pression. These experimental data provide evidence that
Brachyury could promote EMT of hepatoma cells via
Akt/Snail-dependent pathway. It was hypothesized that
Brachyury might activate cytoplasmic Akt signal path-
way to repress the tumor suppressor PTEN. Overexpres-
sion of PTEN has been reported to strongly inhibit the
EMT of mesoderm cells. The functions of PTEN as a
negative regulator of the PI3K/Akt pathway via dephos-
phorylation of PtdIns(3,4,5)P(3) has been reported, partici-
pating in regulation of EMT during cancer progression
[39]. The study data demonstrated that PTEN expression
was significantly influenced by Brachyury overexpression.
However, more evidence is required to confirm whether
PTEN expression is directly regulated by Brachyury.
To summarize, Brachyury could play an important role
in HCC metastasis by EMT induction via, at least par-
tially, PTEN/AKT/Snail-dependent pathway; and it may
serve as a valuable prognostic biomarker and potential
therapeutic target. The present study results uncovered a
novel function and molecular mechanism for Brachyury
in HCC which will shed new light on the understanding
of tumor progression and metastasis.
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